

# openheart Conceptual model for early health technology assessment of current and novel heart valve interventions

Simone A Huygens,<sup>1,2,3</sup> Maureen P M H Rutten-van Mólken,<sup>2,3</sup> Jos A Bekkers,<sup>1</sup> Ad J J C Bogers,<sup>1</sup> Carlijn V C Bouten,<sup>4</sup> Steven A J Chamuleau,<sup>5</sup> Peter P T de Jaegere,<sup>6</sup> Arie Pieter Kappetein,<sup>1</sup> Jolanda Kluin,<sup>7</sup> Nicolas M D A van Mieghem,<sup>6</sup> Michel I M Versteegh,<sup>8</sup> Maarten Witsenburg,<sup>6</sup> Johanna J M Takkenberg<sup>1</sup>

**To cite:** Huygens SA, Rutten-van Mólken MPMH, Bekkers JA, *et al.* Conceptual model for early health technology assessment of current and novel heart valve interventions. *Open Heart* 2016;**3**:e000500. doi:10.1136/openhrt-2016-000500

► Additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/openhrt-2016-000500>)

Received 14 July 2016  
Accepted 2 August 2016



CrossMark

For numbered affiliations see end of article.

**Correspondence to**  
Simone A Huygens;  
s.huygens@erasmusmc.nl

## ABSTRACT

**Objective:** The future promises many technological advances in the field of heart valve interventions, like tissue-engineered heart valves (TEHV). Prior to introduction in clinical practice, it is essential to perform early health technology assessment. We aim to develop a conceptual model (CM) that can be used to investigate the performance and costs requirements for TEHV to become cost-effective.

**Methods:** After scoping the decision problem, a workgroup developed the draft CM based on clinical guidelines. This model was compared with existing models for cost-effectiveness of heart valve interventions, identified by systematic literature search. Next, it was discussed with a Delphi panel of cardiothoracic surgeons, cardiologists and a biomedical scientist (n=10).

**Results:** The CM starts with the valve implantation. If patients survive the intervention, they can remain alive without complications, die from non-valve-related causes or experience a valve-related event. The events are separated in early and late events. After surviving an event, patients can experience another event or die due to non-valve-related causes. Predictors will include age, gender, NYHA class, left ventricular function and diabetes. Costs and quality adjusted life years are to be attached to health conditions to estimate long-term costs and health outcomes.

**Conclusions:** We developed a CM that will serve as foundation of a decision-analytic model that can estimate the potential cost-effectiveness of TEHV in early development stages. This supports developers in deciding about further development of TEHV and identifies promising interventions that may result in faster take-up in clinical practice by clinicians and reimbursement by payers.

## INTRODUCTION

Heart valve disease represents a major global health burden. The prevalence of heart valve disease in the USA in 2000 was 2.5%.<sup>1</sup> The most common intervention for heart valve

## KEY QUESTIONS

### What is already known about this subject?

- Emerging technological advances in the field of heart valve interventions are often accompanied with high research and development costs. To avoid unsuccessful implementation of new technologies in clinical practice, it is essential to investigate the potential cost-effectiveness of new technologies before implementation in clinical practice using early health technology assessment (HTA) techniques. Early HTA investigating particular requirements for novel heart valve interventions to become cost-effective in the future is not yet available.
- An example of an emerging technological advance is tissue-engineered heart valves. In situ tissue engineering provides a promising method to create heart valves with potential to grow, repair and last a lifetime. They have the potential to limit or perhaps even eliminate the disadvantages of existing heart valve substitutes (eg, use of anticoagulation drugs and need for reoperations because of valve degeneration).

### What does this study add?

- The paper provides a conceptual model (CM) to study the cost-effectiveness of currently available heart valve interventions and novel heart valve interventions, such as tissue-engineered heart valves.

### How might this impact on clinical practice?

- Based on the CM, we can build a decision-analytic model to inform stakeholders about the cost-effectiveness of current heart valve interventions and the potential cost-effectiveness of novel heart valve interventions. The results of this early HTA will especially be useful for the developers of tissue-engineered heart valves because it can guide them in further development of the interventions. However, it also helps clinicians and healthcare payers in identifying promising applications of tissue-engineered heart valves, which may result in faster take-up in clinical practice and reimbursement by healthcare payers.

disease is surgical valve replacement with mechanical or biological heart valve substitutes. There is no perfect heart valve substitute as every heart valve substitute type has its own limitations.<sup>2</sup> The future promises many emerging technologies in the field of heart valve interventions. For example, tissue-engineered heart valves that are expected to be introduced in clinical practice in the next decade.<sup>3 4</sup>

The scarcity of resources for healthcare implies that choices must be made regarding healthcare spending on current and novel heart valve interventions. This problem will only become more important in the future, since it is expected that healthcare costs will continue to rise due to ageing populations and development of new medical technologies.<sup>5</sup> Health technology assessment (HTA) can support healthcare decision makers in allocating the limited resources in a way that maximises the health of the overall population and avoids implementation of ineffective or comparatively inefficient interventions.<sup>6</sup> Currently, the cost-effectiveness is often evaluated when the new intervention is ready for introduction in clinical practice to demonstrate healthcare payers that the new intervention is good value for money. However, at that time it may be too late to change the technology to better fit the needs of clinical practice in light of already existing treatment options. To avoid wasting large research and development (R&D) investments, developers should already ask themselves questions like: “What properties should the new technology minimally have to improve clinical outcomes in patients?” and “What are the maximum additional costs of the new technology compared to current treatments in order for the new technology to become cost-effective?” early in the development process. Early HTA is a form of HTA that evaluates technologies in development to support biomedical developers in maximising the return on investment and societal impact of the new technology.<sup>7</sup> This could improve the pace and the efficiency of the development and guarantee successful implementation of the new technology in clinical practice in the future.<sup>8</sup>

This research is part of the Netherlands Cardio Vascular Research Initiative (CVON) IValve consortium that aims to develop the first in-human tissue-engineered heart valves. To support the developers in the development of tissue-engineered heart valves, we are in the process of developing a decision-analytic model for the early HTA of tissue-engineered heart valves. In a decision-analytic model evidence from different sources on health outcomes, health-related quality of life and societal costs can be combined. The appropriate development of a decision-analytic model begins with understanding the problem that is being represented by defining a conceptual model (CM).<sup>9</sup> This study describes the process of developing the CM for early HTA novel heart valve interventions, especially tissue-engineered heart valves.


## METHODS

The development of the CM was based on recommendations from ISPOR-SMDM Modeling Good Research

Practices Task Force-2.<sup>9</sup> Figure 1 provides a schematic overview of the CM development process described in this paper. First, we scoped the decision problem and developed a draft CM. Next, we performed a systematic literature review to compare the structure of the draft CM with existing decision-analytic models. Finally, we organised a Delphi panel to validate the CM with experts and finalise the model.

### Scoping and draft CM

It is important to elucidate the nature of the problem under consideration, modelling objectives and scope before constructing the model.<sup>9</sup> Therefore, the problem definition, patient population, current treatment options, perspective, outcomes and time horizon were defined within a small workgroup (SH, MR, JT). Subsequently, the workgroup developed a draft CM using literature and clinical guidelines. Possible predictors of health outcomes were derived from The Working Group on Valvular Heart Disease of the European



**Figure 1** Schematic overview of the development process of the CM. CM: conceptual model.

Society of Cardiology<sup>10</sup> and the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease.<sup>11</sup>

### Literature review

The complete methods of the systematic review of existing decision-analytic models on the cost-effectiveness of heart valve interventions will be reported elsewhere. In short, in May 2015, several databases were searched using key words regarding economic evaluations, models, heart valve disease and implantations. Publications were included when they reported model-based economic evaluations considering costs and health outcomes of heart valve implantations. Papers solely describing regression models, cost analyses, non-English publications, conference proceedings or abstracts, editorials and letters to the editor were excluded. References of the selected papers and previous systematic reviews were crosschecked for other relevant studies.

For the purpose of the development of the CM, study and model characteristics of included studies were extracted. Study characteristics included target population, patient characteristics, valve position, intervention of interest and comparator(s), location (ie, country) and study perspective. Model characteristics included the type of decision-analytic model, model health states, health outcomes, time horizon, cycle length (in Markov models) and discount rates. Additionally, we extracted cost-effectiveness results and critically appraised the methodological quality of the studies, but these results will be reported elsewhere.

### Expert opinion

To assess whether the events and treatment options in the model represents clinical practice, we presented the CM to experts. This process was divided into two parts.

First, we discussed the draft CM with a cardiothoracic surgeon and intervention cardiologist in our hospital. The following topics were discussed: general understanding and completeness of the model, overlap between model elements, consideration of valve-related events on the short and/or long term and combining valve-related events in composite events. Afterwards, we adapted the structure of the model based on the input of the experts.

Second, we gathered opinions of eight other experts from our (n=4) and other hospitals in the Netherlands (n=4) using a Delphi panel.<sup>12</sup> Altogether, the Delphi panel consisted of 10 panellists: 5 cardiothoracic surgeons, 4 cardiologists and 1 biomedical scientist. In the first round of the Delphi panel, we held individual semi-structured interviews with the panellists to explain the structure of the model, to discuss the events included in the model and their typical treatment options, and to discuss topics that emerged as a result of our systematic literature review. After the experts were interviewed, we converted the collected information into an online

questionnaire. The first questionnaire asked panellists about their opinion on topics other panellists brought up during the interviews. Based on the results of the first questionnaire, we have sent the panellists a second online questionnaire with an updated CM with explanation of the adaptations that were made. This round provided a final opportunity for the Delphi panellists to give suggestions about the CM.

## RESULTS

### Scoping and draft CM

#### Problem definition

We defined the decision problem underlying our model as the choice of a heart valve intervention that results in the most health benefits for specific subgroups of patients at acceptable costs.<sup>2</sup> This includes current and novel heart valve interventions that are being developed and may be introduced in clinical practice in the future. One promising innovation is the development of tissue-engineered heart valves. In situ tissue-engineering provides a promising method where a synthetic biodegradable scaffold in the shape of a valve will be implanted in the patient. The scaffold recruits endogenous cells from the bloodstream and surrounding tissues, these cells form new tissue and gradually transform into a valve.<sup>3</sup> These valves are foreseen to have important advantages: they will respond to patient growth, repair themselves and last a lifetime in the same way as most native valves do.<sup>4</sup>

#### Patients

The patient population of interest includes patients with severe valve stenosis or regurgitation in the aortic or pulmonary position that are deemed candidates for surgical valve replacement or transcatheter valve implantation. We focus on the aortic and pulmonary position because tissue-engineered heart valves are expected to be implanted in these valve positions in the near future.

#### Current treatment options

The current treatment options are defined as surgical valve replacement and transcatheter valve implantation in the aortic or pulmonary valve position. To limit the complexity of the model and data requirements, valve repairs are not taken into account.

The choice of intervention and its outcomes in patients with heart valve disease differs substantially among age groups. To account for these differences, the study population is divided into four age subgroups: 0–18, 19–60, 61–70 and >70 years. The model structure is the same across subgroups, but the treatment options differ and input parameters are to be estimated separately for each age group and valve position. The following age-related considerations were taken into account in defining the age subgroups and corresponding treatment options. In children, the choice of heart valve substitute to use in surgical valve replacement is difficult

because most heart valve substitutes are not able to respond to the patient's growth. This is not the case after the Ross procedure (ie, pulmonary autograft), which may be an alternative for surgical valve replacement with bioprostheses or mechanical valves in patients with aortic valve disease.<sup>13</sup> In addition, pulmonary percutaneous valve intervention is a less invasive alternative for patients who developed dysfunction of the right ventricular outflow tract following neonatal repair of complex congenital heart disease.<sup>14</sup> In young adults, surgical valve replacement with a mechanical valve is generally preferred over bioprostheses because of its longer durability and subsequent lower risk of reoperation.<sup>2</sup> For middle aged patients, surgical valve replacement with biological or mechanical valves are both acceptable.<sup>2</sup> In elderly, bioprostheses are generally preferred because the patients' life expectancy is usually shorter than the durability of the valve and, therefore, they can benefit from the advantages of bioprostheses, such as no need for lifelong anticoagulation.<sup>2</sup> In elderly patients with severe aortic valve disease and a high surgery risk or for those who are not deemed operable because of comorbidities, transcatheter aortic valve implantation (TAVI) may be an alternative.<sup>15</sup>

#### Perspective, outcomes and time horizon

We chose a societal perspective, which means that all relevant costs and benefits are to be taken into account regardless of who bears the costs or enjoys the benefits.<sup>16</sup> The outcome measures were defined as health-related quality of life, event occurrence, event-free survival, valve-related and non-valve-related mortality and societal costs. We decided to adopt a lifetime horizon, modelling outcomes from the start of the intervention until the patient dies.

#### Predictors of outcomes

We identified the following potentially relevant predictors of in-hospital events and mortality in patients with heart valve disease: age, gender, symptomatic status (New York Heart Association class), left ventricular ejection fraction, pulmonary artery systolic pressure,

creatinine, chronic pulmonary disease, extracardiac arteriopathy, neurological impairment affecting daily activity, concomitant coronary artery disease, concomitant coronary artery bypass surgery, type of valve surgery, concomitant surgery of the ascending aorta, redo cardiac surgery, emergency surgery, frailty, major organ system dysfunction and procedure-specific impediments (eg, patients with a porcelain aorta are not suitable for TAVI).<sup>10 11</sup>


#### Draft CM

The draft CM of patient prognosis after heart valve implantation is presented in figures 2 and 3. The model describes health states that individuals can enter. Predictors describe the likelihood of these and subsequent events occurring at various, often continuous, time points (represented as time-to-event). Costs and quality of life weights are to be attached to events and time spent in different health conditions to estimate long-term costs and health outcomes.<sup>17</sup>

The model starts with the valve implantation. Patients can survive the intervention or not. When patients survive the intervention, they can remain 'alive', die from non-valve-related causes or experience a valve-related event. Patients experiencing an event can die without receiving treatment or receive treatment for the event. After treatment patients can die or survive the event. When patients survive the event, they can stay alive, experience another event or die due to non-valve-related causes. The quality of life and costs of being alive after an event depend on the experienced event. The transition probabilities of patients moving from one health condition to another depend on predictors.

Figure 3 provides a detailed explication of the same CM as presented in figure 2. In figure 3 the valve-related events and treatment options are specified and the events are divided into early (<30 days after the intervention) and late events. The definitions of these events are based on clinical outcome reporting guidelines.<sup>18 19</sup> Some events are more common in patients undergoing transcatheter valve implantation than surgical valve

**Figure 2** Draft simple CM for the early HTA of tissue-engineered heart valves. CM: conceptual model; HTA: health technology assessment.



replacement and vice versa. However, to be able to compare interventions, all events are to be included for every intervention.

### Literature review


The systematic literature review identified 14 studies reporting decision-analytic models for economic evaluation of heart valve implantations.<sup>20–33</sup> The following elements in the structures of existing models were remarkable and were discussed with the experts to determine whether and how these elements should be operationalised in our model. First, in the existing models, the events are not as detailed as in our model; when complications are included several valve-related events are combined or less valve-related events are included. Second, the events that are included in the short-term or long-term differ between studies. Third, conversion to surgical aortic valve replacement is sometimes included as option in models considering TAVI.

### Expert opinion


The input from the first two experts resulted in an updated model illustrated in online supplementary appendix figure 1. Subsequently, we recruited eight additional experts resulting in a Delphi panel with 10 panellists. The updated CM was discussed with seven of the eight panellists during semistructured interviews. After the interviews, two rounds of online questionnaires were sent out to all 10 panellists. The first questionnaire was answered by eight panellists and the second

questionnaire by 10 panellists. The results of the input from the first two experts and the Delphi panel are described in detail in online supplementary appendix 2. The following describes the most important changes that were made based on the expert's opinions to obtain the final CM (figure 4).

- ▶ The events are separated into cardiovascular, non-cardiovascular and prosthetic valve-related events to obtain a logic model structure. All events in the model are related to the heart valve intervention, but the events in the category 'prosthetic valve-related events' are directly related to the heart valve substitute.
- ▶ The following events are considered only during the first 30 days after the intervention because after that period the events are not necessarily related to the intervention: myocardial infarction, vascular complications, atrial fibrillation, pacemaker implantation and acute kidney injury. The other events are to be considered during the rest of the patient's lifetime using time-to-event rates.
- ▶ The event 'stroke' is redefined as 'cerebrovascular accident' to include strokes and transient ischaemic attacks.
- ▶ Except for atrial fibrillation during the first 30 days after the intervention, conduction disturbances and arrhythmias are only included in the model when they result in pacemaker implantation. Otherwise these events were considered less relevant.
- ▶ The distinction between acute and progressive deterioration of valve function was found to be unrealistic



**Figure 3** Draft detailed CM for the early HTA of current and novel heart valve interventions. \*Within 30 days after the intervention. CM: conceptual model; HTA: health technology assessment.



**Figure 4** Final CM for the early HTA of current and novel heart valve interventions. Cerebrovascular accident includes strokes and transient ischemic attacks. Prosthetic valve dysfunction includes structural valve deterioration (SVD), non-structural valve dysfunction (NSD) and valve-malpositioning. Treatment includes the typical treatment strategies for the events in the model (table 1). Background and excess mortality: Some of the non-valve-related mortality will be comparable with mortality in the general population (background mortality). The remaining non-valve-related mortality can be ascribed to the excess risk of dying of patients who underwent heart valve interventions (excess mortality). The excess mortality can be explained by increased occurrence of sudden death, underreporting of valve-related events, and underlying pathology such as left ventricular hypertrophy. CM: conceptual model; HTA: health technology assessment.

because the (changes in) the rate of deterioration can often not be established in clinical practice. Therefore, these events are combined into one event called ‘prosthetic valve dysfunction’, including structural valve deterioration, non-structural valve dysfunction and valve malpositioning.

- ▶ Instead of the general term ‘embolism’ two severe consequences of embolism—stroke and myocardial infarction—are included in the model to avoid double counting of events.
- ▶ Conversions from transcatheter valve implantation to open surgery and vice versa are added to the model.
- ▶ The group of events ‘Other TAVI-related complications’ is excluded from the model as a separate category. Instead, these events are included in other categories of events or excluded (see online supplementary appendix 2 for more details).

In addition to inclusion of events in the CM, the typical treatment strategies for the events were discussed with the Delphi panellists. Based on their advice, we included the most common treatment options presented in table 1.

## DISCUSSION

This study provided a CM to perform early HTA of tissue-engineered heart valves expected to be used in clinical practice in the future. By using a comprehensive approach, including a systematic literature review and input from a Delphi panel with experts, the CM developed in this study has become a valuable representation of the most important consequences after heart valve interventions.

The CM serves as the foundation of the decision-analytic model that will be used to perform early HTA of tissue-engineered heart valves. Although the model is developed for tissue-engineered heart valves, it can also be applied to estimate the cost-effectiveness of currently used heart valve interventions and other novel heart valve interventions such as minimally invasive valve surgery and robotically assisted valve surgery.

Before we can perform cost-effectiveness analyses with our decision-analytic model, data need to be collected on the input parameters of the model. Three types of input parameters can be distinguished: (1) time spent in health states and transition probabilities (chance of

**Table 1** Typical treatment strategies of events included in the CM

Cardiovascular events	
Cerebrovascular accident	Conservative management (antiplatelets and/or anticoagulants and watchful waiting) Thrombolysis (in-hospital) Mechanical thrombectomy
Myocardial infarction	Conservative management Percutaneous coronary intervention Coronary artery bypass grafting
Vascular complication	Conservative management (in-hospital monitoring with duplex sonography) Endovascular stent or balloon therapy Surgical repair
Bleeding	Optimization of anticoagulation control Blood transfusion Surgical repair of bleeding location Re-intervention*
Atrial fibrillation (without PI)	Medication (anticoagulants)
Conduction disturbances and arrhythmias	Electric cardioversion Pacemaker implantation (PI)†
Non-cardiovascular events	
Acute kidney injury	Conservative management (diuretics to correct volume overload) Continuous veno-venous hemofiltration Chronic dialysis Kidney transplant
Prosthetic valve-related events	
Prosthetic valve dysfunction	Conservative management (heart failure medication and watchful waiting) Re-intervention*
Prosthetic valve thrombosis	Thrombolysis (in-hospital) Re-intervention: valve replacement
Prosthetic valve endocarditis	Antibiotic treatment (in-hospital) Re-intervention: valve replacement

\*Re-intervention can be surgical repair or replacement/valve-in-valve implantation of another valve substitute.

†Patients with conduction disturbances and arrhythmias other than atrial fibrillation without the need for pacemaker implantation are excluded.

CM: conceptual model.

In early HTA, the interventions under study are not used in clinical practice yet. Therefore, we will need to make assumptions about the input parameters for tissue-engineered heart valves. These assumptions will be based on the results of animal studies and expert opinion of biomedical scientists developing tissue-engineered heart valves and clinicians. The accompanying uncertainty of these assumptions will be analysed using exploratory sensitivity and scenario analyses.

In contrast to tissue-engineered heart valves, the input parameters for the current standard of care can be based on real-world evidence. Time spent in health states and transition probabilities will be based on clinical data registries and systematic reviews and meta-analysis.<sup>34</sup> Healthcare costs are currently being estimated using claims data from health insurers. Quality of life and costs outside of healthcare (ie, productivity and informal care costs) are collected using patient-reported questionnaires.

Once the input parameters are collected, we can use our decision-analytic model to perform the following analyses. First, the cost-effectiveness of currently used heart valve substitutes can be determined. Second, a benchmark can be set for the minimum performance requirements and maximum costs of tissue-engineered heart valves to be cost-effective compared to currently used heart valve substitutes. If it is not likely that the performance requirements will be met or when the costs of the new intervention appear to be too high compared to currently used heart valve substitutes, continuing investment in tissue-engineered heart valves may not be worthwhile. Third, when it seems feasible to meet the performance requirements and implant tissue-engineered heart valves under the maximum allowed costs to be cost-effective, more detailed cost-effectiveness analyses can be performed by simulating various scenarios with the decision-analytic model. In these scenarios, the impact of different assumptions on the performance and costs on the cost-effectiveness of tissue-engineered heart valves can be simulated. These scenario analyses can be modified and repeated as more information becomes available during the development process of tissue-engineered heart valves. Fourth, we can also use our decision-analytic model to determine the probabilities and size of return on investments of developers of tissue-engineered heart valves. The potential revenue can be calculated by multiplying the difference in the proposed sales price and expected production costs of tissue-engineered heart valves with the expected number of patients per year.<sup>35</sup> Relevant scenarios with different estimates of the sales price, production costs, number of patients per year and speed of adoption of the novel heart valve intervention can be simulated. Finally, a budget impact analysis can be performed to address the expected changes in the expenditure of the national healthcare system after the adoption of the new heart valve intervention. These analyses can inform healthcare decision makers and health insurers about potential financial consequences.

moving from one health state to another), (2) quality of life weights and (3) societal costs of patients, in every health state in the CM.

The results of early HTA can be useful for different stakeholders. First, it provides guidance to developers of tissue-engineered heart valves in further development of the technology, setting realistic performance-price goals, and designing and managing reimbursement strategies.<sup>36</sup> Second, it informs clinicians about future treatment options that may result in faster adoption of tissue-engineered heart valves in clinical practice.<sup>37</sup> Finally, healthcare payers are informed earlier about potential interventions that may enter the market in the future, which may result in more timely decisions about reimbursement.<sup>37</sup>

Despite the potentials of (early) HTA, there are also limitations. First, all models represent a simplification of reality. Therefore, decisions had to be made about what is relevant to include. This study enables readers to gain insight in the choices that were made and the reasons for making simplifying assumptions when necessary. Second, there were some events for which consensus could not be reached within the Delphi panel: including transient ischaemic attacks in addition to stroke, excluding or including atrial fibrillation during the first 30 days after the intervention and including myocardial infarction and pacemaker implantation during the first 30 days after the intervention instead of over the patient's lifetime. In these cases, the small workgroup (SH, MR, JT) decided about the inclusion of these events. However, these decisions may alter the results of the model.<sup>9</sup> In case sufficient data are available, we can perform sensitivity analysis for these events to determine their influence on the outcomes. Third, although most panellists initially did not agree, we had to decide to model the various types of prosthetic valve dysfunction in the same way because it is not feasible to incorporate different rates of deterioration of quality of life because of limited data availability. However, the majority of the panellists did not object to this decision in the final questionnaire.

## CONCLUSIONS

The future promises many emerging technologies in the field of heart valve interventions. Prior to implementation in clinical practice it is essential to perform early HTA to inform stakeholders about the potential return on investment and societal impact of the new technology. In this study we developed a CM that will be used as the foundation of a decision-analytic model that can estimate the cost-effectiveness of current heart valve interventions and the potential cost-effectiveness of novel heart valve interventions in the early development stages, especially tissue-engineered heart valves. The results of this early HTA will especially be useful for the developers of tissue-engineered heart valves because it can guide them in further development of the interventions. However, it also helps clinicians and healthcare payers in identifying promising applications of tissue-engineered heart valves, which may result in faster take-up in clinical practice and reimbursement by healthcare payers.

## Author affiliations

<sup>1</sup>Department of Cardio-Thoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands

<sup>2</sup>Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

<sup>3</sup>Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands

<sup>4</sup>Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands

<sup>5</sup>Department of Cardiology, University Medical Centre, Utrecht, The Netherlands

<sup>6</sup>Department of Cardiology, Erasmus University Medical Centre, Rotterdam, The Netherlands

<sup>7</sup>Department of Cardio-Thoracic Surgery, Academic Medical Centre, Amsterdam, The Netherlands

<sup>8</sup>Department of Cardio-Thoracic Surgery, Leiden University Medical Centre, Leiden, The Netherlands

**Acknowledgements** The authors acknowledge the support from the Netherlands Cardio Vascular Research Initiative: The Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences.

**Funding** The study was supported by the Netherlands Cardio Vascular Research Initiative (CVON).

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

- Nkomo VT, Gardin JM, Skelton TN, *et al.* Burden of valvular heart diseases: a population-based study. *Lancet* 2006;368:1005–11.
- Vahanian A, Alfieri O, Andreotti F, *et al.* Guidelines on the management of valvular heart disease (version 2012) The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2012;33:2451–96.
- Bouten CV, Driessen-Mol A, Baaijens FP. In situ heart valve tissue engineering: simple devices, smart materials, complex knowledge. *Expert Rev Med Devices* 2012;9(5):453–5.
- Mol A, Smits AIPM, Bouten CVC, *et al.* Tissue engineering of heart valves: advances and current challenges. *Expert Rev Med Devices* 2009;6:259–75.
- de Meijer C, Wouterse B, Polder J, *et al.* The effect of population aging on health expenditure growth: a critical review. *Eur J Ageing* 2013;10:353–61.
- Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? *Eur J Health Econom* 2003;3:143.
- Ijzerman MJ, Steuten LMG. Early assessment of medical technologies to inform product development and market access. *Appl Health Econ Health Policy* 2011;9:331–47.
- Markiewicz K, van Til JA, Ijzerman MJ. Medical devices early assessment methods: systematic literature review. *Int J Technol Assess Health Care* 2014;30:137–46.
- Roberts M, Russell LB, Paltiel AD, *et al.* Conceptualizing a model a report of the ISPOR-SMDM modeling good research practices task force–2. *Med Decis Mak* 2012;32:678–89.
- Rosenhek R, lung B, Tornos P, *et al.* ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. *Eur Heart J* 2012;33:822–8.



11. Nishimura RA, Otto CM, Bonow RO, *et al.*, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63:2438–88.
12. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. *Pract Assess Res Eval* 2007;12:1–8.
13. Takkenberg JJ, Klieverik LM, Schoof PH, *et al.* The Ross procedure a systematic review and meta-analysis. *Circulation* 2009;119:222–8.
14. Ghawi H, Kenny D, Hijazi ZM. Transcatheter pulmonary valve replacement. *Cardiol Therapy* 2012;1:1–14.
15. Genereux P, Head SJ, Wood DA, *et al.* Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. *Eur Heart J* 2012;33:2388.
16. Rutten-van Mölken MPMH, Groot CA, Al MJ. *Van kosten tot effecten: een handleiding voor economische evaluatiestudies in de gezondheidszorg*. Elsevier Gezondheidszorg, 2010.
17. Kamon J, Stahl J, Brennan A, *et al.* Modeling using discrete event simulation a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—4. *Med. Decis Mak* 2012;32:701–11.
18. Akins CW, Miller DC, Turina MI, *et al.* Guidelines for reporting mortality and morbidity after cardiac valve interventions. *Eur J Cardiothorac Surg* 2008;33:523–8.
19. Kappetein AP, Head SJ, Génereux P, *et al.* Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. *J Am Coll Cardiol* 2012;60:1438–54.
20. Beresniak A, Sabatier B, Achouh P, *et al.* Cost-effectiveness of mitral valve repair versus replacement by biologic or mechanical prosthesis. *Ann Thorac Surg* 2013;95:98–104.
21. Brecker S, Mealing S, Padhiar A, *et al.* Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. *Open Heart* 2014;1:e000155.
22. Doble B, Blackhouse G, Goeree R, *et al.* Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. *J Thorac Cardiovasc Surg* 2013;146:52–60.e3.
23. Fairbairn TA, Meads DM, Hulme C, *et al.* The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. *Heart* 2013;99:914–20.
24. Gada H, Kapadia SR, Tuzcu EM, *et al.* Markov model for selection of aortic valve replacement versus transcatheter aortic valve implantation (without replacement) in high-risk patients. *Am J Cardiol* 2012;109:1326–33.
25. Gada H, Agarwal S, Marwick TH. Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: outcomes of a decision-analytic model. *Ann Cardiothorac Surg* 2012;1:145–55.
26. Hancock-Howard RL, Feindel CM, Rodes-Cabau J, *et al.* Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings. *J Med Econ* 2013;16:566–74.
27. Murphy A, Fenwick E, Toff WD, *et al.* Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. *Int J Technol Assess Health Care* 2013;29:12–19.
28. Neyt M, Van Brabant H, Devriese S, *et al.* A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. *BMJ Open* 2012;2:pil: e001032.
29. Orlando R, Pennant M, Rooney S, *et al.* Cost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation. *Health Technol Assess* 2013;17:1–86.
30. Queiroga MAC, Nishikawa AM, Paladini LM, *et al.* Transcatheter aortic valve implantation for the treatment of severe aortic valve stenosis in inoperable patients under the Perspective of the Brazilian Supplemental health system—cost-effectiveness analysis. *Rev Bras Cardiologia Invasiva* 2013;21:213–20.
31. Report to Scottish Health Technologies Group (SHTG). Evidence Development Pilot Project: Transcatheter Aortic Valve Implantation in Scotland, 2010. [http://www.gla.ac.uk/media/media\\_218806\\_en.pdf](http://www.gla.ac.uk/media/media_218806_en.pdf) (accessed Oct 2016).
32. Simons CT, Cipriano LE, Shah RU, *et al.* Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis a cost-effectiveness analysis. *Circ Cardiovasc Qual Outcomes* 2013;6:419–28.
33. Watt M, Mealing S, Eaton J, *et al.* Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. *Heart* 2012;98:370–6.
34. Huygens SA, Mokhles MM, Hanif M, *et al.* Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2016;50:605–16.
35. Cosh E, Girling A, Lilford R, *et al.* Investing in new medical technologies: a decision framework. *J Commercial Biotechnol* 2007;13:263–71.
36. Pietzsch JB, Paté-Cornell ME. Early technology assessment of new medical devices. *Int J Technol Assess Health Care* 2008;24:36–44.
37. Buisman LR, Rutten-van Mölken MP, Postmus D, *et al.* The early bird catches the worm: early cost-effectiveness analysis of new medical tests. *Int J Technol Assess Health Care* 2016;32:46–53.